Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with bladder, urothelial, or prostate cancer — whether the cancer is confined to the original organ or has spread — where a tissue sample can be taken from the primary site, a bone deposit, or a soft tissue deposit with low risk of complications
- People without cancer (men and women) who are willing to have blood or normal tissue collected during a procedure already being done for their routine care (for example, a procedure to remove prostate or bladder tissue); no extra tissue beyond what is needed for their care would be taken
- People who are at risk of developing cancer and are willing to have blood or normal tissue collected during a routine, non-research procedure
- People who have previously collected (archival) tissue stored from a research or routine care procedure and are willing to donate it for this study
- People who are able to understand the study information and agree to take part
- People whose blood test results meet these minimum levels: platelet count above 50,000, white blood cell count above 1,500, haemoglobin above 8.0, and whose blood clotting tests (INR below 1.5 and PTT below 45) are within acceptable ranges
- People with no history of unexplained excessive bleeding during or after previous surgery
Who may not be able to join:
- People who are not able to safely stop blood-thinning medications (such as warfarin or Lovenox/enoxaparin) for fewer than 3 days before a biopsy procedure
- People who have a serious or uncontrolled infection at the time of the study
- People who have received a VEGF-inhibitor medication (a type of drug that blocks blood vessel growth, such as bevacizumab/Avastin) within the past 28 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert B. Montgomery, Fred Hutch/University of Washington Cancer Consortium
Phone: 206-598-0856
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
DNA genomic sequencing; Gene expression profile using microarray assays; Mutation mapping using the OncoMap and other genotyping techniques
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.